Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
50
resultados
Última actualización
02/08/2026 [06:45:00]
Resumen de: US20260217723A1
0000 Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Resumen de: AU2025210712A1
Disclosed herein are novel compounds that are Mpsl/TTK inhibitors. Also disclosed herein are compositions comprising the compounds and methods of using the compounds in treating various diseases in a patient. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.
Resumen de: US20260218197A1
The present invention provides a novel secretion reducing agent and novel secretion reducing method for reducing extracellular vesicle secretion from cells. The extracellular vesicle secretion reducing agent of the present invention is characterized in that it contains an inhibitor of a serine synthesis pathway. The cells are, for example, cancer cells such as colorectal cancer cells, lung cancer cells, melanoma cells, breast cancer cells, pancreas cancer cells, and multiple myeloma cells.
Resumen de: US20260217788A1
Provided herein is a method of treating a subject who has a cancer. At least one dose of chimeric antigen receptor (CAR)-T cells comprising a CAR comprising a polypeptide is administered to the subject. The peptide comprises an extracellular antigen binding domain with at least two BCMA-binding moieties, a transmembrane domain, and an intracellular signaling domain. The dose of CAR-T cells administered to the subject is from 4.0×105 to 1.0×106 of CAR-T cells per kilogram of the subject's mass. Alternatively, the dose comprises 1×106 to 1×108 of the CAR-T cells.
Resumen de: US20260216138A1
0000 Provided is a composition for targeting OTUD7B. The composition includes a component sufficient to block or reduce OTUD7B-mediated deubiquitination of GβL in a cell. The component can include 7Bi and variants thereof. Also provided are methods of treating cancer and related conditions, including administering to a cancer patient a OTUD7B catalytic inhibitor, including a 7Bi or variant thereof.
Resumen de: US20260218307A1
Described herein are methods for diagnosing and treating mycosis fungoides (MF) and cutaneous T cell lymphoma (CTCL), e.g., for making a differential diagnosis of CTCL/MF versus other skin conditions.
Resumen de: US20260216204A1
0000 The present disclosure relates to the use of pelabresib, and pharmaceutically acceptable salts and hydrates thereof, for treating lower risk myelodysplastic syndrome (LR-MDS) and conditions associated therewith.
Resumen de: EP4782010A1
0001 The use of an anti-CD20 antibody-drug conjugate or a pharmaceutical combination thereof in the preparation of a drug for treating non-Hodgkin lymphoma. The pharmaceutical combination comprises the anti-CD20 antibody-drug conjugate and at least one therapeutic agent. Compared with existing clinical second-line standard therapies, combination therapy using the anti-CD20 antibody-drug conjugate or the pharmaceutical combination comprising same has a better therapeutic effect.
Resumen de: EP4782436A2
Disclosed herein are compounds, 6-substituted-2-(1,1'-biphenyl-4-yl)quinoline-4-carboxylic acid analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Resumen de: US20260209271A1
Disclosed herein is a series of helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9, and selectively disrupt β-catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin/BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.
Resumen de: US20260207557A1
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
Resumen de: US20260209298A1
0000 The present invention is to confirm that PLK1 induces tumor formation and cancer metastasis through IGFBP5 phosphorylation, and provide an IGFBP5 mutant in which a region phosphorylated by PLK1 is mutated and a vector expressing same. The IGFBP5 mutant of the present invention maintains a binding ability to PLK1, and thus binds to PLK1 overexpressed competitively with wild-type IGFBP5 in cancer cells, thereby making it possible to inhibit tumor formation and cancer metastasis, and the provision of a vector expressing the mutant in cancer cells can inhibit cancer mobility and invasiveness and inhibit tumor formation. The mutant of the present invention is safe because it does not affect the inherent function of IGFBP5 in normal cells, and thus can be useful in the treatment of various diseases caused by abnormal cell growth, especially degenerative diseases such as primary and metastatic solid cancer and leukemia.
Resumen de: US20260207710A1
0000 Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering (a) an IL-2 conjugate, and (b) a chimeric antigen receptor (CAR) therapy. Also disclosed herein are methods for treating diffuse large B-cell lymphoma (DLBCL) in a subject in need thereof, comprising administering an IL-2 conjugate.
Resumen de: US20260209356A1
0000 The present invention concerns a vector including the cassette coding for B7-H3 CAR gene obtained using the single chains variable fragments (scFv) of the monoclonal IgG antibody NE97, a method for the production thereof and B7-H3 CAR genetically modified effector cells (such as T cells or innate cells such as NK and NK-T cells) for the treatment of CD276 (B7-H3) positive tumors such as lymphoid malignancies, leukemia and solid tumors such as CNS tumors, extra-cranial and intracranial tumors and autoimmune diseases.
Resumen de: US20260207742A1
0000 Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and/or acute lymphoblastic leukemia.
Resumen de: WO2026154051A1
The present invention relates to gliptins, the inhibitors of dipeptidyl peptidase 4, also known as DPP-4 inhibitors, for use in the treatment and/or prevention of diseases in a human subject. The present invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of gliptins, pharmaceutically acceptable salts thereof and hydrates thereof, for use in a therapeutic or prophylactic method of treating a MALT-1 involving disease in a subject, preferably selected from allergic inflammatory disease, an autoimmune disease, multiple myeloma and glioma, in a human subject in need thereof. The present invention also relates to the use of gliptins as an allosteric MALT1 inhibitor for use in a method of treating a MALT-1 involving disease in a subject, preferably selected from an allergic inflammation disease, multiple sclerosis, multiple myeloma and glioma. The present invention is also directed to the field of personalized cancer care and treatment.
Resumen de: US20260207738A1
Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
Resumen de: US20260209308A1
0000 Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×10<5 >to 5.0×10<6 >of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
Resumen de: US20260207757A1
0000 Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
Resumen de: WO2026152242A1
The present invention relates to a polysaccharide with cytotoxic activity against human colon, human lung, human melanoma and murine leukaemia tumour cells, as well as antioxidant and healing activity. The invention also relates to a method for producing the polysaccharide, its uses and applications, particularly via drugs for treating cancer and/or antioxidant and healing compositions. The polysaccharide of the present invention can be produced from biomass, particularly from fungi, and preferably from the fungus Bovistella utriformis.
Resumen de: US20260200878A1
The objective of the present invention is to provide a novel 2-((trans-4-(4-aryloxy)cyclohexyl)amino)quinazolinone derivative which exhibits anti-cancer activity through elF2α phosphorylation efficacy, wherein the novel synthesized derivative exhibits an eIF2α phosphorylation effect and cancer cell proliferation inhibitory activity in vitro, and thus can be used as a metabolic anti-cancer drug in pharmaceutical and health functional food compositions for preventing and ameliorating leukemia and other rare cancers such as breast cancer, brain tumor, and sarcoma.
Resumen de: US20260199335A1
0000 The present disclosure relates to compounds of Formula 1 and pharmaceutical compositions thereof for the treatment of cancer in a subject having a mutant form of NPM1, DNMT3A, RAS, or a combination thereof, or for specific treatments of subjects with relapsed or treatment-refractory (R/R) acute myeloid leukemia (AML).
Resumen de: US20260201476A1
The present disclosure provides methods of treating acute myeloid leukemia (AML) and methods of determining responsiveness to AML treatment regimens, including regimens comprising the administration of a BCL-2 inhibitor, a hypomethylating agent, a CD70-targeting agent, or any combination thereof, the methods comprising identifying the presence or absence of one or more biomarkers described herein.
Resumen de: US20260199343A1
The present disclosure provides methods of administering belumosudil to patients with multiple myeloma.
Nº publicación: US20260199361A1 16/07/2026
Solicitante:
ACROTECH BIOPHARMA INC [US]
ACROTECH BIOPHARMA INC
Resumen de: US20260199361A1
0000 The present disclosure provides compositions comprising Pralatrexate for subcutaneous administration. The present disclosure also provides methods of administering the compositions comprising Pralatrexate, as disclosed herein, for the treatment of disease (e.g., lymphoma).
BOPI
Sede Electrónica
